about
Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell FateHigh intensity focused ultrasound inhibits melanoma cell migration and metastasis through attenuating microRNA-21-mediated PTEN suppression.Synthetic lethality: emerging targets and opportunities in melanoma.Concurrent BRAF and PTEN mutations in melanoma of unknown origin presenting as a breast mass.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradationGenotyping of cutaneous melanoma.Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.Voltage-sensing phosphatase modulation by a C2 domainInhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Mathematical Modelling of Molecular Pathways Enabling Tumour Cell Invasion and Migration.Revisiting determinants of prognosis in cutaneous melanoma.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.Melanoma m (zero): diagnosis and therapy.CTGF is a therapeutic target for metastatic melanoma.PTEN and melanomagenesis.Targeted therapy for melanoma: rational combinatorial approaches.Rho-associated coiled-coil kinase (ROCK) signaling and disease.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Prognostic and predictive biomarkers in melanoma: an update.PTEN regulates IGF-1R-mediated therapy resistance in melanoma.Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.Patient-derived tumor xenograft models for melanoma drug discovery.Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Effect of PTEN antisense oligonucleotide on oesophageal squamous cell carcinoma cell lines.Interaction of molecular alterations with immune response in melanoma.Genomic characterisation of acral melanoma cell lines.Skin cancer: symptoms, mechanistic pathways and treatment rationale for therapeutic delivery.Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients.Mutational and expressional analyses of PTEN gene in colorectal cancer from Northern India.Multiplex assessment of protein variant abundance by massively parallel sequencing
P2860
Q30234505-9542D58B-1710-4024-9DD2-5651056661B7Q30365568-853FD911-ACC8-468D-8C68-633E822F331DQ33578398-6EF1889A-9920-49B3-9C29-EA9288C9E0EFQ33757319-04B953DB-2896-43BA-9C42-04100FEA8514Q33917630-06CCB100-64EB-4651-8E0E-D731E0AD5AE0Q34518472-1B42B21E-C543-496E-BDEA-BB931AF73F13Q34667738-BA1E153C-FB5F-4ADF-99E3-B39FC2DE9189Q35140496-C19450C2-9988-48A6-8F5C-66228AE73FA4Q35313400-029735B3-B13B-4542-9FE0-E5D490208551Q35746524-A7ACD1AB-522E-4AC1-827B-7789D1FC6CC9Q35830233-F8FAC6E2-3CF7-4B54-9340-35D491A344A5Q36338825-F1CD021F-EF8F-4B3E-9D7A-D34760632C89Q36553576-8B52A571-CA8E-4D0D-B6E9-B203AD4FD8B8Q36741115-5E6876AB-2B4D-4E4C-A9B1-383ADAC0A833Q36830323-A9E637D8-7C45-4F3E-BA69-31A9BFA3FEFDQ37662627-007994DC-1892-453C-859B-8C18AB3C081AQ38048884-E8284F52-D473-4CA0-9F74-3D59275CF500Q38082327-949141F0-7C24-4DD2-88E0-73BEDAE6FC29Q38100279-22476DC3-90C0-4C7F-B8FD-422C5C3DDC4AQ38148747-BA6E5BD5-F530-48DA-B02F-E805FC8EE24EQ38219616-0536664E-1729-4AD5-B833-C4EBF8B6DF45Q38653619-E428C318-DD1F-4EC0-AF4C-E90E3C5E25C7Q38859960-6522F615-5AD9-4DCC-B4CB-25290D9309F8Q38860973-9232BE8F-A2C3-45A2-AF2A-67115E534C49Q38907413-80B6E7B2-057D-47F3-887D-91B9BDC20BFBQ38943508-E304110D-B49F-4DC2-85C7-68C252F9C4EEQ38998443-F487BE99-E0CB-456F-BA05-5FA9DD05DBE5Q39173195-5D36FB6D-26E4-4DE1-AEC1-064B67003727Q39210082-017A5706-6E68-4135-BAA8-A5D35838370EQ39329609-4ED42688-0298-44F6-B23B-75473030E2BBQ39349974-D128A13C-AF06-4026-8BD7-31E8111838E3Q42507904-2CBD5BA6-321E-48CD-B422-3AA01EF18AC8Q45269149-1FC896DD-26E0-448C-AB8F-8203A9CF675DQ47134263-E06AA99D-1428-4B02-884A-E06007993EA2Q53068627-4A9F7EA5-F802-44F8-A8E1-30CAA53E2F8FQ54273990-4EA20FFD-F85B-4EAC-B010-113DC1F15CE3Q57475860-E5B12D9C-C8A5-4CF6-A6B7-70172979A804
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Genetic alterations of PTEN in human melanoma.
@en
Genetic alterations of PTEN in human melanoma.
@nl
type
label
Genetic alterations of PTEN in human melanoma.
@en
Genetic alterations of PTEN in human melanoma.
@nl
prefLabel
Genetic alterations of PTEN in human melanoma.
@en
Genetic alterations of PTEN in human melanoma.
@nl
P2860
P1476
Genetic alterations of PTEN in human melanoma.
@en
P2093
Almass-Houd Aguissa-Touré
P2860
P2888
P304
P356
10.1007/S00018-011-0878-0
P577
2011-11-11T00:00:00Z